TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18379058

Group type: EXPERIMENTAL
Intervention: 6% w/v d-limonene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-limonene (100 mumol/kg/body wt for 5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cumulative skin irritation and sensitization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patch adhesion
Number of subjects: 0
Study: 16441467

Group type: EXPERIMENTAL
Intervention: 1-week triple therapy for eradication of H. pylori
Number of subjects: 51

Group type: COMPARATOR
Intervention: Omeprazole plus placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Crossover open-label triple therapy
Number of subjects: 51
Study: 12969090

Group type: EXPERIMENTAL
Intervention: HM-CAP (immunoglobulin-G)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: PP-CAP (immunoglobulin-A)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pyloriset EIA-G
Number of subjects: 93
Study: 10710743

Group type: EXPERIMENTAL
Intervention: GnRH agonist leuprolide acetate, 3.75 mg intramuscularly every 28 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 9018513

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (120 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise with Pseudoephedrine
Number of subjects: 10
Study: 1588267

Group type: EXPERIMENTAL
Intervention: 8-hour intensive training course on interpretation of electrocardiography in myocardial infarction
Number of subjects: 16

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 16
Study: 3903644

Group type: EXPERIMENTAL
Intervention: Metoclopramide (1 mg/kg, intravenous)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bethanechol (0.075 mg/kg, subcutaneous)
Number of subjects: 10
Study: 31348415

Group type: EXPERIMENTAL
Intervention: The First Twenty® (TF20) program, a web-based health and wellness program with nutrition, physical activity, and behavioral health components.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 10
Study: 29066028

Group type: EXPERIMENTAL
Intervention: Group B2: 80 kVp, 30 ml of iohexol at 4.5 ml/s; hybrid iterative reconstruction (HIR) and IMR.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group A: 120 kVp, 50 ml of iopromide at a flow rate of 5 ml/s; filtered back projection (FBP) reconstruction.
Number of subjects: 60
Study: 28683245

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nasal congestion index (NCI)
Number of subjects: 48
Study: 24041792

Group type: EXPERIMENTAL
Intervention: ITX5061 150 mg/day for 28 days (C150)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ITX5061 150 mg/day for 3 days (A150)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ITX5061 150 mg/day for 14 days (B150)
Number of subjects: 30
Study: 22705785

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus strain L-55-contained yogurt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 0
Study: 19798072

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Number of subjects: 234
Study: 19558057

Group type: EXPERIMENTAL
Intervention: 5000 IU of intravenous heparin during surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 50
Study: 16023510

Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Number of subjects: 177

Group type: COMPARATOR
Intervention: Rectal diazepam
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Buccal midazolam and Rectal diazepam
Number of subjects: 177
Study: 12399203

Group type: EXPERIMENTAL
Intervention: H-B-VAXII (0.5 ml, 5 micro g HBsAg) intramuscular injection at birth, 1, and 6 months (Schedule A)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: H-B-VAXII (0.5 ml, 5 micro g HBsAg) intramuscular injection at birth, 1, 2, and 12 months (Schedule B)
Number of subjects: 97
Study: 10344062

Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lisinopril 2.5 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 7855576

Group type: EXPERIMENTAL
Intervention: Central bearing point method
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Protrusive check-bite method
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Protrusive bite record integrated in the bite fork
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All methods combined
Number of subjects: 40
Study: 1775523

Group type: EXPERIMENTAL
Intervention: Prazepam (30‐60 mg)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Clomipramine (75‐150 mg)
Number of subjects: 118
Study: 6126413

Group type: EXPERIMENTAL
Intervention: Timiperone
Number of subjects: 205

Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 205
Study: 31804659

Group type: EXPERIMENTAL
Intervention: Standard multimodal treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31446437

Group type: EXPERIMENTAL
Intervention: Single-Operator Cannulation Technology (SOCT) for ERCP
Number of subjects: 69

Group type: COMPARATOR
Intervention: Regular ERCP procedure
Number of subjects: 69
Study: 27580151

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Calorie restriction and exercise (CREX)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (EX)
Number of subjects: 52
Study: 27595142

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg intravenous infusion given over 2 h at baseline, and again at 2 weeks and 6 weeks after the first infusion)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Ciclosporin (2 mg/kg per day by continuous infusion for up to 7 days, followed by twice-daily tablets delivering 5.5 mg/kg per day for 12 weeks)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 270

Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 270
Study: 25068741

Group type: EXPERIMENTAL
Intervention: Concept mapping (experimental group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 41
Study: 20881846

Group type: EXPERIMENTAL
Intervention: quetiapine XR (50-300 mg/day)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: quetiapine XR
Number of subjects: 432

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 432
Study: 19404190

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 17301634

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with endurance training (ET)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) without endurance training (ET)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard care with endurance training (ET)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 17
Study: 15008646

Group type: EXPERIMENTAL
Intervention: Competitive decision maker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prosocial value orientation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selfish value orientation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategic misrepresentation
Number of subjects: 0
Study: 11334128

Group type: EXPERIMENTAL
Intervention: PACQLQ intervention
Number of subjects: 62
Study: 9879918

Group type: EXPERIMENTAL
Intervention: Intensive fluoride mouthrinsing (10 ml of 0.045% NaF neutral solution once a day for 3 days, twice a year, totaling 6 rinses per year)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Fluoride-free tap water rinsing (control group)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Intensive fluoride mouthrinsing (among caries-free at baseline)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Fluoride-free tap water rinsing (among caries-free at baseline)
Number of subjects: 139
Study: 7977190

Group type: EXPERIMENTAL
Intervention: Fränkel functional appliance
Number of subjects: 43

Group type: COMPARATOR
Intervention: Headgear
Number of subjects: 43
Study: 2525449

Group type: EXPERIMENTAL
Intervention: Clinofibrate (200 mg, three times daily for 16 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (200 mg, three times daily for 16 weeks)
Number of subjects: 20
Study: 29753264

Group type: EXPERIMENTAL
Intervention: 1 mg dexamethasone
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (0 mg dexamethasone)
Number of subjects: 85
Study: 25795409

Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine (cisplatin 75 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine (paclitaxel 175 mg/m² on day 1 and gemcitabine 1250 mg/m² on days 1 and 8)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine
Number of subjects: 240
Study: 23816964

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) plus prednisone (P)
Number of subjects: 1195

Group type: COMPARATOR
Intervention: Prednisone (P) alone
Number of subjects: 1195
Study: 20649689

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/d with or without medroxyprogesterone acetate (MPA, 10 mg/d)
Number of subjects: 2304

Group type: EXPERIMENTAL
Intervention: CEE alone therapy
Number of subjects: 2304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2304
Study: 18250074

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Stroke Impact Scale (SIS) version 3.0 questionnaire
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 30
Study: 16608015

Group type: COMPARATOR
Intervention: QHBS in asymptomatic controls
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: QHBS in SO stenosis group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: QHBS in SO dyskinesia group
Number of subjects: 28
Study: 15363253

Group type: EXPERIMENTAL
Intervention: Portal vein chemotherapy (5‐fluorouracil infusion at 1g per day for 7 days after operation)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Intraluminal chemotherapy (5‐fluorouracil 0.5 g injected during operation)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 162
Study: 11215556

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (Group 1)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Normal unrestricted diet (Group 2)
Number of subjects: 39
Study: 9024252

Group type: EXPERIMENTAL
Intervention: Recombinant GH treatment for 9 months (adjusted for body surface area) in men
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Recombinant GH treatment for 9 months (adjusted for body surface area) in women
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Recombinant GH treatment for 9 months in men
Number of subjects: 36
Study: 8274360

Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (366 mg Mg2+/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-supplementation measurements
Number of subjects: 0
Study: 3095501

Group type: EXPERIMENTAL
Intervention: Chex‐UP chemotherapy (four-drug combination: cyclophosphamide, hexamethylmelamine, 5‐fluorouracil, and cisplatin)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) 5‐FU (6 cycles)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Chex‐UP chemotherapy
Number of subjects: 62
Study: 29641631

Group type: EXPERIMENTAL
Intervention: Stabilization of the graft material with a fixed temporary appliance
Number of subjects: 0

Group type: COMPARATOR
Intervention: No temporary reconstruction (control group)
Number of subjects: 0
Study: 26340411

Group type: EXPERIMENTAL
Intervention: TEG-guided transfusion strategy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 60
Study: 24589454

Group type: EXPERIMENTAL
Intervention: IVD-A
Number of subjects: 1459

Group type: EXPERIMENTAL
Intervention: IVD-B
Number of subjects: 1459

Group type: COMPARATOR
Intervention: NSV
Number of subjects: 1459
Study: 22933426

Group type: COMPARATOR
Intervention: NSAID use at baseline
Number of subjects: 160143

Group type: EXPERIMENTAL
Intervention: NSAID use at both baseline and year 3
Number of subjects: 160143
Study: 20113301

Group type: EXPERIMENTAL
Intervention: Multimodal school-based group CBT (8 sessions)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No intervention (clinical control group)
Number of subjects: 56
Study: 17928044

Group type: EXPERIMENTAL
Intervention: Intervention program focusing on the production of non-canonical sentences, specifically training in object-relative-clauses and who-questions.
Number of subjects: 7
Study: 15890758

Group type: EXPERIMENTAL
Intervention: Moderate doses of training (3-6 months)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Heavy doses of training (12 months)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (Masters athletes aged 68 +/- 3 years and healthy sedentary young individuals aged 29 +/- 6 years)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Training in seniors
Number of subjects: 10
Study: 12807838

Group type: EXPERIMENTAL
Intervention: Bjork-Shiley prosthesis
Number of subjects: 533

Group type: COMPARATOR
Intervention: Porcine prosthesis
Number of subjects: 533
Study: 10830566

Group type: EXPERIMENTAL
Intervention: 20-week standard group continuing care intervention
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Individualized relapse prevention continuing care intervention
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Patients with APD
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Patients without APD
Number of subjects: 127
Study: 8798349

Group type: COMPARATOR
Intervention: Low-molecular-weight heparins (LMWH) alone (Group A: n = 591)
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: Combination of Daflon 500 mg with LMWH (Group B: n = 595)
Number of subjects: 1372

Group type: COMPARATOR
Intervention: Low-molecular-weight heparins (LMWH) alone (Group C: n = 93)
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: Combination of Daflon 500 mg with LMWH (Group D: n = 93)
Number of subjects: 1372
Study: 1458667

Group type: EXPERIMENTAL
Intervention: 0.125% amorolfine cream
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: 0.25% amorolfine cream
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: 0.5% amorolfine cream
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: 1% bifonazole cream
Number of subjects: 232
Study: 6085004

Group type: EXPERIMENTAL
Intervention: 9 beta-methyl carbacyclin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epoprostenol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9 beta-methyl carbacyclin and Epoprostenol
Number of subjects: 0
Study: 29663871

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg for men; 12 mg for women)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 27906432

Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy (DT 50 Gy, 2.0 Gy/fraction, 25 times, during 33-35 days)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Concurrent radio chemotherapy and intensity modulated radiotherapy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Concurrent radio chemotherapy and hypofractionation (DT of 42.56 Gy, 2.66Gy/fraction, 16 times, during 22-24 days)
Number of subjects: 112
Study: 23910578

Group type: EXPERIMENTAL
Intervention: Prophylaxis with FEIBA NF (85 ± 15 U kg(‐1) every other day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: On-demand treatment with FEIBA NF
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prophylaxis with FEIBA NF
Number of subjects: 36
Study: 22368077

Group type: EXPERIMENTAL
Intervention: No headrest
Number of subjects: 100

Group type: COMPARATOR
Intervention: Headrest
Number of subjects: 100
Study: 20493549

Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg, 4 mg, or 8 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 0
Study: 19137769

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pimecrolimus cream
Number of subjects: 0
Study: 15832627

Group type: EXPERIMENTAL
Intervention: Deeper processing during encoding (semantic, phonemic, or graphemic questions) for twice-presented items
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deeper processing during encoding (semantic, phonemic, or graphemic questions) for once-presented items
Number of subjects: 0
Study: 12001553

Group type: EXPERIMENTAL
Intervention: Headgear Herbst appliance and step-by-step advancement (HHSSA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional Herbst appliance with maximal jumping (HMJ)
Number of subjects: 45
Study: 10459591

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 7823996

Group type: EXPERIMENTAL
Intervention: Bed rest for two days
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Back-mobilizing exercises
Number of subjects: 186

Group type: COMPARATOR
Intervention: Ordinary activities as tolerated (Control)
Number of subjects: 186
Study: 2505712

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg orally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perindopril 2 mg orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg orally
Number of subjects: 0
Study: 335203

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Alprenolol
Number of subjects: 24
Study: 30782118

Group type: EXPERIMENTAL
Intervention: Multimodal and multidisciplinary program including consultations with a geriatrician and a dietician, and a physical training program from a personal trainer.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 0
Study: 29446817

Group type: EXPERIMENTAL
Intervention: Depressed Type 2 diabetic patients (T2DP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anxiety in Type 2 diabetic patients (T2DP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anxious-depressive co-morbidity in Type 2 diabetic patients (T2DP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mood disorders in Type 2 diabetic patients (T2DP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dysthymia in Type 2 diabetic patients (T2DP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isolated depressive episode in Type 2 diabetic patients (T2DP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Glycemic control in depressed vs non-depressed Type 2 diabetic patients (T2DP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Factors associated with depression in Type 2 diabetic patients (T2DP)
Number of subjects: 100
Study: 25774559

Group type: EXPERIMENTAL
Intervention: Compliance Therapy (up to six weekly sessions)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Wait-list control (standard care)
Number of subjects: 18
Study: 23382960

Group type: EXPERIMENTAL
Intervention: Capsaicin cream
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 25
Study: 21314752

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 74
Study: 19081418

Group type: EXPERIMENTAL
Intervention: ABT-335 + simvastatin 20 mg
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: ABT-335 + simvastatin 40 mg
Number of subjects: 657

Group type: COMPARATOR
Intervention: simvastatin 20 mg
Number of subjects: 657

Group type: COMPARATOR
Intervention: simvastatin 40 mg
Number of subjects: 657

Group type: COMPARATOR
Intervention: ABT-335 monotherapy (135 mg)
Number of subjects: 657
Study: 17888840

Group type: EXPERIMENTAL
Intervention: Patients with reduced eGFR
Number of subjects: 603

Group type: COMPARATOR
Intervention: Patients with normal renal function
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Baseline differences in LVMI
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: LVMI and LA volume
Number of subjects: 603
Study: 11093292

Group type: EXPERIMENTAL
Intervention: Short walks (10 min brisk walking before each meal)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Long walk (30 min brisk walking before breakfast)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Walking (combined short and long walks)
Number of subjects: 10
Study: 8942424

Group type: EXPERIMENTAL
Intervention: 3,4-didehydroretinyl acetate (DRA) administered at standard doses: 5.3 mumol for children < 6 y, 7.0 mumol for children 6-12 y, 8.8 mumol for adults and children > 12 y.
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: DRA in vitamin E-containing corn oil, with or without 4.6 mmol all-rac-alpha-tocopheryl acetate/L.
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: DRA stored in amber glass vials.
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 3,4-didehydro-retinol to retino ratio.
Number of subjects: 84
Study: 1848053

Group type: EXPERIMENTAL
Intervention: Towne live attenuated virus vaccine
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 6220334

Group type: EXPERIMENTAL
Intervention: Almitrine (60 mg/24 h)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Duxil (5023 SE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Raubasine (20 mg/24 h)
Number of subjects: 30
Study: 31010346

Group type: EXPERIMENTAL
Intervention: Super Skin Rejuvenation (SSR) 540 nm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pixel Q-switched Nd: YAG (PQSNDY) 1064 nm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ablative pixel-Er: YAG (2940 nm)
Number of subjects: 60
Study: 29324776

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 577

Group type: COMPARATOR
Intervention: Control (direct infertility treatment)
Number of subjects: 577